Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma

• Published in: International journal of oral science Vol. 12; no. 1; p. 16
• Main Authors: Mei, Zi, Huang, Junwen, Qiao, Bin, Lam, Alfred King-yin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.05.2020; Springer Nature B.V
• Subjects: 631/67/1059/2325; 631/67/1536/1665; Apoptosis; CD223 antigen; Cell activation; Cell death; Clinical trials; CTLA-4 protein; Cytotoxicity; Dentistry; Glucocorticoids; Head & neck cancer; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Humans; Immune checkpoint; Immunoglobulins; Immunologic Factors - therapeutic use; Immunoreceptor tyrosine-based inhibition motif; Immunotherapy; Immunotherapy - methods; Lymphocytes T; Medicine; Mucin; Oral and Maxillofacial Surgery; Orthopedics; PD-1 protein; Review; Review Article; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - pathology; Squamous Cell Carcinoma of Head and Neck - therapy; Surgical Orthopedics; Tumor Microenvironment; Tumor necrosis factor; Tumors; Tyrosine

With the understanding of the complex interaction between the tumour microenvironment and immunotherapy, there is increasing interest in the role of immune regulators in the treatment of head and neck squamous cell carcinoma (HNSCC). Activation of T cells and immune checkpoint molecules is important...